Robert Lookstein, MD, is the executive vice chairman of the department of diagnostic, molecular, and interventional radiology at the Icahn School of Medicine at Mount Sinai.

STORM-PE: Computer-Assisted Vacuum Thrombectomy Outperforms Anticoagulation, With Robert Lookstein, MD

The STORM-PE trial has proven the superiority of computer-assisted vacuum thrombectomy (CAVT) with anticoagulation (AC) versus AC alone in reducing right-to-left-ventricular (RV/LV) diameter ratio within 48 hours in patients with intermediate to high risk of 

 sat down with Robert Lookstein, MD, executive vice chairman of the department of diagnostic, molecular, and interventional radiology at the Icahn School of Medicine at Mount Sinai, to discuss the implications of this study and the future of CAVT technology. Lookstein explained the difference between existing models and CAVT, highlighting its potential for improving PE care.

“CAVT was a significant advancement in the field for many reasons,” Lookstein told 

. “First and foremost, it is a relatively smaller size, and it’s less rigid, so the introduction of the catheter causes less strain on the heart. Secondly, the physician performing the procedure doesn’t need to use a syringe to extract the clot; the catheter is attached to a vacuum pump. And then, overarching the entire procedure, is the computer microprocessor that’s built into the catheter, which can sense when the tip of the catheter is touching thrombus instead of just flowing blood or the vessel wall.”

STORM-PE was a prospective, multicenter, randomised, placebo-controlled trial, conducted across 22 locations worldwide. To be included, patients were required to be 18-80 years old, have clinical signs and symptoms of acute PE with a duration ≤14 days, objectively confirmed acute PE based on computed tomographic pulmonary angiography (CTPA), a classification of intermediate high-risk PE as demonstrated by right ventricular dysfunction RV/LV ratio ≥1 on CTPA and elevated cardiac biomarkers, including cardiac troponin, BNP, and/or NT-pro BNP, among other criteria.

Patients were excluded if they exhibited hemodynamic instability with either cardiac arrest, obstructive shock, or persistent hypotension defined as systolic blood pressure <90 mmHg or an acute drop in systolic blood pressure ≥40 mmHg for >15 minutes, as well as having allergy, hypersensitivity, or heparin-induced thrombocytopenia, a creatinine clearance <45 mL/min, and other criteria.

The trial ultimately enrolled 100 patients with a mean age of 59.5 +/- 13.22 years in the CAVT arm and 61.2 +/- 14.19 years in the AC arm. Mean time from PE symptom onset to hospital admission was roughly 3 days (interquartile range [IQR] 0-6) in the CAVT arm and 2 days (0-6) in the AC arm (

 = 0.889). All patients had elevated cardiac biomarkers, and 59.1% in the CAVT arm and 74.5% in the AC arm had both elevated troponin and BNP or NT-proBNP (

Patients were randomly assigned in a 1:1 ratio to either CAVT (n = 47) or AC (n = 53). For the CAVT arm, access was obtained via the femoral vein (4.3% [2/47] left and 95.7% [45/47] right), and the thrombectomy procedure was technically successful in all patients. Median thrombectomy time was 25 minutes (IQR, 15-41), and median procedure time was 56 minutes (IQR, 42-69).

At 48 hours, the change in RV/LV ratio was greater for the CAVT arm (0.52 +/- 0.37) than AC (0.24 +/- 0.4), a difference of 0.27 (95% CI, 0.12-0.43; 

 <.001). Early normalisation of vital signs was also more frequent after CAVT, and the major adverse event rate within 7 days was not different between groups (CAVT 4.3% vs AC 7.5%; 

Ultimately, Lookstein and colleagues determined that CAVT was superior to AC alone in reducing RV/LV ratio, as well as accomplishing an earlier normalisation of vital signs and a comparable rate of major adverse events compared to AC.

“The time that the catheter spent in the patient was incredibly short, arguably the shortest recorded time in the modern cardiovascular era,” Lookstein said. “All trial operators were able to deliver the catheters where the thrombus was located and successfully extract the clot. In other words, the technical success was 100%. There were no complications related to either the insertion or removal of the catheter.”

Editor's Note: Lookstein reports disclosures with Boston Scientific, INARI, Penumbra, Ethicon, Instylla, Imperative Vascular, and others.

Lookstein RA, Konstantinides SV, Weinberg I, et al. Randomized controlled trial of mechanical thrombectomy with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism: Primary outcomes from the storm-PE trial. Circulation. Published online November 3, 2025. 

Penumbra Inc. Comparison of Two Pulmonary Embolism Treatments. ClinicalTrials.gov Identifier: NCT05684796. Updated November 17, 2025. Accessed November 25, 2025. 

https://clinicaltrials.gov/study/NCT05684796

Videos

CAVT effectively reduced right-to-left ventricular diameter ratio within 48 hours, with earlier vital sign normalizing and similar adverse event rates to AC.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Venous Thromboembolism

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

 has approved sibeprenlimab (Voyxact) for reducing proteinuria in primary 

 in adults at risk for disease progression, according to a November 25, 2025 update on the agency website. 

A targeted APRIL inhibitor from Otsuka Pharmaceutical Co., sibeprenlimab was examined in the VISIONARY trial, which is billed by Otsuka as the largest phase 3 trial ever conducted in IgAN, where use was associated with a 54.3% placebo-adjusted reduction in geometric mean 24-hour urine protein-to-creatinine ratio (UPCR) from baseline after 12 months of treatment.

"We are confident about the potential of sibeprenlimab and are grateful to the patients who are helping to further the science by participating in these important trials," said John Kraus, MD, PhD, executive vice president and chief medical officer, Otsuka Pharmaceutical Development & Commercialization, Inc, in a June 2025 press release around the presentation of interim UPCR data.

 "Proteinuria control is an important independent predictor for long-term prognosis, and this interim data reinforces our belief that selectively targeting APRIL has the potential to be an effective and safe approach for this progressive and irreversible kidney disease."

The accelerated approval of sibeprenlimab is the latest in a series of regulatory decisions in recent years for IgAN, following accelerated approvals for iptacopan (Fabhalta) in August 2024 and atrasentan (Vanrafia) in April 2025. As of November 2025, sparsentan (Filspari) and budesonide (Tarpeyo) are the only agents to receive full FDA approval to reduce the loss of kidney function in adults with IgAN.

Spanning 31 countries, the VISIONARY trial randomized 510 participants in a 1:1 ratio to sibeprenlimab or placebo therapy for 2 years. According to data from the 

62nd European Renal Association (ERA 2025) Congress

 presentation, 98% of participants were on renin-angiotensin system inhibitors and 39% were also taking SGLT2 inhibitors at baseline.

The 12-month data from the trial, which was presented at the 

American Society of Nephrology (ASN) Kidney Week 2025

, a indicated use was associated with a reduction in24-hour UPCR of 56.6% (95% Confidence Interval [CI], 50.8% to 61.7%) compared with 5.1% (-6.7% to 15.7%) for placebo, yielding a between-group difference of 54.3% (95% CI, 46.4% to 60.9%).

Additional data presented at ASN Kidney Week 2025 indicated sibeprenlimab use was associated with consistent reductions in 24-hour across all evaluated subgroups, including ethnicity, sex at birth, age, race, and SGLT2 inhibitor use at baseline. The largest effects were observed in patients with higher baseline proteinuria (UPCR > 2.0 g/g: 64.7%).

The 12-month data also pointed to reductions in spot UPCR of 51.1% with sibeprenlimab compared to -8.5% with placebo and proteinuric remission (<0.5 g/d) at month 12 occurred in 34.3% of sibeprenlimab-treated patients compared to 12.7% with placebo. Investigators also noted 48-week biomarker reductions in IgA (68.8% vs 23.6%), IgG (35.0% vs 4.6%), IgM (74.5% vs 1.9%), APRIL (95.8% vs 25.5%), and Gd-IgA1 (67.1% vs 1.2%) favored sibeprenlimab over placebo.

The full 2-year results, which will include eGFR, are expected to be released in 2026.

“This is the proteinuria data. It's incredibly promising. The phase 2 GFR data looks, if anything, even more promising, but we need to wait now for the remaining eGFR and other outcome data at 2 years of follow-up,” remarked Perkovic, in an 

US Food and Drug Administration. Novel Drug Approvals for 2025. U.S. Food and Drug Administration. Published November 25, 2025. Accessed November 25, 2025. 

https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025

Perkovic V, Barratt J, Lafayette RA, et al. Sibeprenlimab for the Treatment of IgAN: VISIONARY Phase 3 Interim and Prespecified Subgroup Analyses. Presented at: ASN Kidney Week. Houston, Texas. November 05-09, 2025.

Otsuka Pharmaceutical Co. Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)｜News Releases | Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Co., Ltd. Published June 6, 2025. Accessed June 6, 2025. 

https://www.otsuka.co.jp/en/company/newsreleases/2025/20250606_1.html

Roberts L, Jones M, Barratt J, Selvaskandan H. IgA nephropathy: a paradigm shift in treatment strategies. 

Articles

The FDA has approved sibeprenlimab for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk of disease progression. This approval follows the VISIONARY trial, which demonstrated a significant reduction in urine protein-to-creatinine ratio with sibeprenlimab compared to placebo. The trial involved 510 participants across 31 countries, with most on renin-angiotensin system inhibitors. Interim data showed consistent proteinuria reductions across subgroups, with notable biomarker improvements. Full 2-year results, including eGFR data, are anticipated in 2026, potentially influencing future IgAN treatment strategies.

FDA grants accelerated approval for sibeprenlimab for reducing proteinuria in IgA nephropathy.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

FDA News

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy 

Kassandra Holzem, MD, is an assistant professor of Dermatology at the Medical College of Wisconsin.

Tips on Patient Communication in Dermatology, With Kassandra Holzem, MD

 interview highlighted the need for a delicate balance between deciding when to call for emergency care among patients in 

, as well as the need for transparency with patients.

This interview featured Kassandra Holzem, MD, assistant professor of Dermatology at the Medical College of Wisconsin, who spoke with the team at the 

2025 Society of Dermatology Physician Associates (SDPA) Fall Conference

 in San Antonio, Texas. Holzem was asked about takeaways from ‘Difficult Cases & Red Flags in Dermatology: When to Admit From the Clinic,’ and specifically about issues related to whether patients are skeptical about hospital admission if it is recommended.

“That definitely factors into it,” Holzem said. “Obviously, ERs are very busy nowadays. Frequently, patients will wait for a really long time too, especially depending on what time of day they're going or what day of the week it is…I think it's something that you just have to be open and honest with your patients about, saying, ‘Listen, I need you to go to the emergency room. You might have to wait a while, but I'm worried that this could be very severe or worrisome for you if you weren't treated in that setting.’”

Additionally, Holzem highlights concerns over cost as a factor impacting patient decisions to admit themselves to an emergency room. Nevertheless, she stressed the importance of communication with patients about risks versus benefits.

“I do think transparency is important, because I think then the patients relate better to you and understand what to expect,” Holzem explained. “...I think also, if you, as a clinician, have the opportunity to directly admit, sometimes we do. We are at institutions that are affiliated with a hospital, and so we might be able to page someone called the admitting medical officer and talk to them directly, and admit from the clinic. That's sometimes a possibility. If we do that, then they actually can bypass the ER, which is really nice. I will say, there are usually a lot of hurdles and headaches with that…but that's something to consider if you do have the ability to do so.”

To find out more on this topic, view Holzem’s full video segment posted above. For more information covered at SDPA, view the 

The quotes implemented in Holzem’s video summary were edited for clarity.

Holzem had no relevant financial disclosures of note.

Holzem K. Difficult Cases & Red Flags in Dermatology: When to Admit From the Clinic. Presented at the Society of Dermatology Physician Associates (SDPA) Fall Conference, November 5-9, San Antonio, TX.

Holzem K, Goff H. Stump the Experts. Presented at the Society of Dermatology Physician Associates (SDPA) Fall Conference, November 5-9, San Antonio, TX.

Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A meta-analysis of 79 randomized controlled trials (RCTs) found high uptake (92%) but moderate adherence and notable failure to complete outcome assessments in mental health app users, with engagement improved by reminders and human support.

“These preliminary patterns provide a useful foundation for future experimental research,” wrote study investigator Claudia Liu, PhD, from SEED Lifespan Strategic Research Centre at Deakin University, in Australia, and colleagues. “Beyond informing future app development, these findings also hold clinical relevance. Clinicians are increasingly asked to recommend or integrate apps into care, and our results suggest which features may help sustain patient engagement. Moreover, knowledge of typical adherence benchmarks can help clinicians set realistic expectations with patients and support them in maintaining app use over time.”

In the past 5 years, telehealth and digital mental health apps have been on the rise, offering convenience, cost-effectiveness, and tailored treatment. The global market for mental health apps is expected to reach > $17 billion by 2030.

Although RCTs support mental health apps for managing depression and anxiety, concerns remain about engagement and attrition.

In this study, investigators examined patterns of uptake, adherence, and attrition of 79 RCTs evaluating mental health apps for 

 and anxiety. The team leveraged studies from a 2024 review of RCTs on depression and anxiety apps, as well as conducted an updated search in Medline and PsycINFO from January 2024 to May 2025.

The RCTs included 92 app conditions and 78 control conditions. The sample included 49.4% with depression, 17.7% with general anxiety, 17.7% with mixed depression and anxiety, 6.3% with social anxiety, 3.8% with specific phobia, and 5.1% with panic disorder. App features included engagement reminders (70.7%), CBT-based (66.3%), symptom monitoring (52.2%), personalization features (39.1%), instructions for recommended use (38%), professional guidance (30.4%), and gamification elements (17.4%). Most trials (78.5%) included human contact. Control group types included waitlist (46.2%), placebo (24.4%), care as usual (17.9%), active therapy (5.1%), and other (6.4%).

The analysis demonstrated the high uptake of mental health apps (92.4%; 95% prediction interval [PI], 48.4% - 99.4%) across 56 conditions. More than half of users stayed on the app (61.8%; 95% PI, 53.2%-69.7%) from 21 conditions.

“This high uptake rate is promising, as it suggests that the vast majority of participants enrolled in these trials were willing to engage with an app,” investigators wrote.

 “However, these encouraging rates from controlled trials are unlikely to reflect real-world use because trial participants are typically more motivated than the general population. In naturalistic settings, uptake has been reported as low as 2% in some countries, underscoring the need to address barriers to digital health adoption.”

The study found users had lower attrition rates (18.6%; 95% CI, 2.4% - 68.3%). By follow-up, attribution rates increased nearly 10 points (28.4%; 95% PI, 3.0% - 83.7%). Investigators observed that study features that support accountability, including reminders and human contact, reduce dropout, while gamified elements did not improve, and might weaken, retention.

The research also showed participants assigned to app interventions tended to drop out more than participants on waitlists, based on the estimated risk ratio of 1.49, indicating a 49% higher dropout. However, the prediction interval is wide (0.34–6.48), meaning the true effect could range from substantially lower to much higher attrition, reflecting high variability across studies. When comparing the app groups to other types of control conditions, such as active controls or placebo apps, the attrition rates were not meaningfully different.

“When contextualized against other modalities, our pooled attrition estimates are comparable with those observed in traditional treatments: approximately 17% in face-to-face psychotherapy trials and 15% to 30% in pharmacotherapy trials,” investigators wrote.

 “This suggests that dropout is not unique to apps but rather reflects a broader challenge across mental health.”

Liu C, Torous J, Fuller-Tyszkiewicz M, et al. Uptake, Adherence, and Attrition in Clinical Trials of Depression and Anxiety Apps: A Systematic Review and Meta-Analysis. 

. Published online November 19, 2025. doi:10.1001/jamapsychiatry.2025.3439

The Growth of Mental Health Apps and Teletherapy: Why They’re So Popular | Jackson Health System. Jackson Health System. Published 2025. https://jacksonhealth.org/the-growth-of-mental-health-apps-and-teletherapy-why-theyre-so-popular/

A meta-analysis of 79 RCTs revealed high uptake (92%) but moderate adherence and notable attrition in mental health app users. Engagement improved with reminders and human support, while gamification did not enhance retention. The study highlighted the importance of understanding adherence benchmarks to set realistic expectations for app use in clinical settings. Despite promising uptake rates in trials, real-world adoption remains low, emphasizing the need to address barriers to digital health adoption. Attrition rates in app interventions were comparable to traditional treatments, indicating a broader challenge across mental health modalities.

A study showed that users readily adopt mental health apps, but adherence and follow-up completion lag; reminders and human support improve engagement.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention 

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Data from an analysis of 3 registries across continents show consistent maternal, neonatal, and long-term graft outcomes, confirming that 

The comparative analysis of registries from the Netherlands, Australia/New Zealand, and the United States attests to the possibility of successful post-kidney-transplantation pregnancies despite elevated risks, reaffirming the importance of close clinical surveillance of mother, fetus, and graft. Further global data harmonization is important to support clinicians managing these high-risk pregnancies.

“Pregnancy outcomes appear consistent across the registries, despite the differences in population size and methodology,” wrote study investigator Styliani Giapoutzidou, MSc, a student researcher in obstetrics and nephrology at the University of Groningen, and colleagues.

 “Pregnancy post-kidney transplant recipients are classified as high-risk. However, the risk can be moderated through advance planning and close monitoring.”

Following kidney transplantation, fertility typically returns quickly to levels sufficient for conception. Female patients are generally advised to wait ≥1 year before attempting to become pregnant. The increasing frequency of pregnancies in kidney transplant recipients calls for improved understanding among clinicians and patients and an expansive effort to collect comprehensive outcome data.

To address this gap in research, investigators reviewed data from 3 major registries.

Pregnancy After Renal Transplantation OUTcomes (PARTOUT), retrospective analysis of pregnancies 1971–2017 in the Netherlands.

The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), annual surveys of all KTR parenthood events since 1968.

The Transplant Pregnancy Registry International (TPRI), a US/international voluntary registry of pregnancies since 1991.

Investigators noted both alignment and methodological differences across PARTOUT, ANZDATA, and TPRI. Mean gestational age was approximately 35 weeks in all registries, while mean birth weight was 2383 g for PARTOUT, 2360 g (median) for ANZDATA, and 2551 g for TPRI. Regarding pregnancy outcomes, PARTOUT reports live births only after 20 weeks’ gestation, whereas ANZDATA and TPRI also include miscarriages before 20 weeks. All 3 registries define stillbirth as occurring after 20 weeks. Ectopic pregnancies are reported only by TPRI, while pregnancy terminations are reported by ANZDATA and TPRI.

Across the 3 registries, reported live birth rates ranged from 75–95%. Long-term graft outcomes were generally consistent, with graft loss occurring in 23% of PARTOUT recipients at a median of 6.44 years post-delivery, 27% of ANZDATA participants at a median follow-up of 8.08 years, and 33% of TPRI participants at a median follow-up of 14.4 years. These findings highlight the importance of ongoing post-pregnancy monitoring of kidney function in transplant recipients, even several years after delivery.

“What is the next step? Establishing global datasets with increased data acquisition should enable improved identification of predictors of pregnancy and newborn complications and should include data from populations potentially under-represented in the existing registries,” investigators concluded.

Study investigators proposed the creation of a future global dataset focused on standardising core variables, aligning definitions across registries, and securely pooling deidentified data. Collaborators would define research questions, outcomes, and analyses upfront, establish inclusive authorship, and create sustainable processes for ongoing updates. This approach aimed to strengthen evidence and improve guidance for clinicians managing high-risk pregnancies in kidney transplant recipients.

Giapoutzidou S, Hewawasam E, Gosselink ME, et al. Pregnancy after kidney transplantation: global insights based on registry data from three continents. 

. Published online November 22, 2025. doi:

https://doi.org/10.1007/s40620-025-02451-x

Pregnancy, Fertility, and Babies after a Kidney Transplant. National Kidney Foundation. Published November 8, 2024. 

https://www.kidney.org/kidney-topics/pregnancy-fertility-and-babies-after-kidney-transplant

Pregnancy after kidney transplantation is feasible with careful monitoring, as evidenced by consistent maternal, neonatal, and graft outcomes across registries from the Netherlands, Australia/New Zealand, and the United States. Despite elevated risks, successful pregnancies are possible, emphasizing the need for close clinical surveillance. Fertility typically returns quickly post-transplant, and women are advised to wait at least one year before conceiving. The study highlights the importance of global data harmonization to improve management of high-risk pregnancies and suggests creating a global dataset to standardize variables and enhance clinical guidance.

International registry analysis highlights consistent outcomes, calls for global collaboration in managing high-risk post-transplant pregnancies.

Women's Health

On the HCPLive women's health page, resources on the topics of medical news and expert insight into obstetrics, gynecology, and women's related health can be found. Content includes articles, interviews, videos, podcasts, and breaking news on women's health, and more.

Global Data Support Successful Pregnancy Outcomes in Kidney Transplant Recipients

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The investigational unimolecular GLP-1 and amylin receptor agonist substantially improved weight loss in a phase 2 trial.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Type 2 Diabetes

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Professor Stephen Nicholls is a world-renowned cardiologist, and leads the Victorian Heart Hospital (VHH) at Monash University.

Nicholls highlights tirzepatide’s capacity to lower the risk of heart failure mortality, as well as hospitalizations or urgent visits.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Atherosclerotic Cardiovascular Disease

Tirzepatide Bests Dulaglutide in Cardiovascular Outcomes in HF, With Stephen Nicholls, MD

Otsuka Pharmaceuticals seeks FDA approval for centanafadine, a novel ADHD treatment, showing significant efficacy in pivotal clinical trials.

ADHD

ADHD condition center page is a comprehensive resource for clinical news and insights on ADHD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for ADHD.

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

In her SDPA Fall Dermatology Conference interview, Holzem highlights key warning signs for a variety of dermatologic conditions requiring hospital admission.

Difficult Cases and Red Flags in Dermatology, With Kassandra Holzem, MD

Patients with MASLD, advanced CKM stages face higher mortality and liver fibrosis, emphasizing the need for early risk assessment. 


MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Advanced CKM Stages Linked to Mortality and Liver Fibrosis in MASLD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

The panel explores patient attitudes toward oral vs injectable treatments and practical limitations of current oral agents.


Video Series

Current Gaps in Psoriasis Care: Tolerability, Efficacy, and Rate of Response

Panelists discuss how new nonsteroidal therapies improve adherence, comfort, and long-term skin health for children with AD.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Managing Pediatric AD With New Topicals

Explore the mechanisms and differences between PCSK9 inhibitors, including monoclonal antibodies and siRNA, in lowering LDL cholesterol effectively.

Understanding PCSK9 and Its Role in ASCVD Management

Panelists discuss how JAK-targeting topical therapies offer effective, well-tolerated solutions for children with mild to moderate AD.

Ruxolitinib Efficacy and Safety in Pediatric AD

Review of the updated IPC framework defining topical failure, reducing “topical churn,” and guiding earlier systemic escalation.

Latest News

STORM-PE: Computer-Assisted Vacuum Thrombectomy Outperforms Anticoagulation, With Robert Lookstein, MD

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

Tips on Patient Communication in Dermatology, With Kassandra Holzem, MD

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Global Data Support Successful Pregnancy Outcomes in Kidney Transplant Recipients